抗肺炎链球菌、流感嗜血杆菌和卡他莫拉菌蛋白抗原抗体在生命最初13年的自然发展。

Q2 Biochemistry, Genetics and Molecular Biology
Clinical and Vaccine Immunology Pub Date : 2016-11-04 Print Date: 2016-11-01 DOI:10.1128/CVI.00341-16
Igor C Borges, Dafne C Andrade, Maria Regina A Cardoso, Jorma Toppari, Mari Vähä-Mäkilä, Jorma Ilonen, Mikael Knip, Heikki Hyöty, Riitta Veijola, Olli Simell, Tuomas Jartti, Helena Käyhty, Olli Ruuskanen, Cristiana M Nascimento-Carvalho
{"title":"抗肺炎链球菌、流感嗜血杆菌和卡他莫拉菌蛋白抗原抗体在生命最初13年的自然发展。","authors":"Igor C Borges,&nbsp;Dafne C Andrade,&nbsp;Maria Regina A Cardoso,&nbsp;Jorma Toppari,&nbsp;Mari Vähä-Mäkilä,&nbsp;Jorma Ilonen,&nbsp;Mikael Knip,&nbsp;Heikki Hyöty,&nbsp;Riitta Veijola,&nbsp;Olli Simell,&nbsp;Tuomas Jartti,&nbsp;Helena Käyhty,&nbsp;Olli Ruuskanen,&nbsp;Cristiana M Nascimento-Carvalho","doi":"10.1128/CVI.00341-16","DOIUrl":null,"url":null,"abstract":"<p><p>Conserved protein antigens have been investigated as vaccine candidates against respiratory pathogens. We evaluated the natural development of antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis proteins during childhood. Serum samples were collected from 50 healthy children from their first months to age 13 years (median sampling interval, 6 months). We also analyzed serum samples from 24 adults. Serum IgG antibodies against eight pneumococcal proteins (Ply, CbpA, PspA 1 and 2, PcpA, PhtD, StkP-C, and PcsB-N), three H. influenzae proteins, and five M. catarrhalis proteins were measured using a multiplexed bead-based immunoassay. Antibody levels were analyzed using multilevel mixed-effects regression and Spearman's correlation. Antibody levels against pneumococcal proteins peaked at 3 to 5 years of age and then reached a plateau. Antibody levels against H. influenzae proteins peaked during the second year and then stabilized. Antibody levels against M. catarrhalis proteins peaked during the first year and then slowly decreased. Peak antibody levels during childhood were higher than those of adults. Correlations among pneumococcal antibody levels were highest among anti-CbpA, anti-PcpA, and anti-PhtD antibodies (r = 0.71 to 0.75; P < 0.001). The children presented 854 symptomatic respiratory infections on 586 occasions. Symptomatic respiratory infections did not improve prediction of antibody levels in the regression model. The maturation of immune responses against the investigated pneumococcal proteins shares similarities, especially among CbpA, PcpA, and PhtD. Antibody production against H. influenzae and M. catarrhalis proteins starts early in life and reaches peak levels earlier than antibody production against the pneumococcal proteins. Basal antibody levels are not related to the occurrence of symptomatic respiratory infections.</p>","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"23 11","pages":"878-883"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/CVI.00341-16","citationCount":"10","resultStr":"{\"title\":\"Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.\",\"authors\":\"Igor C Borges,&nbsp;Dafne C Andrade,&nbsp;Maria Regina A Cardoso,&nbsp;Jorma Toppari,&nbsp;Mari Vähä-Mäkilä,&nbsp;Jorma Ilonen,&nbsp;Mikael Knip,&nbsp;Heikki Hyöty,&nbsp;Riitta Veijola,&nbsp;Olli Simell,&nbsp;Tuomas Jartti,&nbsp;Helena Käyhty,&nbsp;Olli Ruuskanen,&nbsp;Cristiana M Nascimento-Carvalho\",\"doi\":\"10.1128/CVI.00341-16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Conserved protein antigens have been investigated as vaccine candidates against respiratory pathogens. We evaluated the natural development of antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis proteins during childhood. Serum samples were collected from 50 healthy children from their first months to age 13 years (median sampling interval, 6 months). We also analyzed serum samples from 24 adults. Serum IgG antibodies against eight pneumococcal proteins (Ply, CbpA, PspA 1 and 2, PcpA, PhtD, StkP-C, and PcsB-N), three H. influenzae proteins, and five M. catarrhalis proteins were measured using a multiplexed bead-based immunoassay. Antibody levels were analyzed using multilevel mixed-effects regression and Spearman's correlation. Antibody levels against pneumococcal proteins peaked at 3 to 5 years of age and then reached a plateau. Antibody levels against H. influenzae proteins peaked during the second year and then stabilized. Antibody levels against M. catarrhalis proteins peaked during the first year and then slowly decreased. Peak antibody levels during childhood were higher than those of adults. Correlations among pneumococcal antibody levels were highest among anti-CbpA, anti-PcpA, and anti-PhtD antibodies (r = 0.71 to 0.75; P < 0.001). The children presented 854 symptomatic respiratory infections on 586 occasions. Symptomatic respiratory infections did not improve prediction of antibody levels in the regression model. The maturation of immune responses against the investigated pneumococcal proteins shares similarities, especially among CbpA, PcpA, and PhtD. Antibody production against H. influenzae and M. catarrhalis proteins starts early in life and reaches peak levels earlier than antibody production against the pneumococcal proteins. Basal antibody levels are not related to the occurrence of symptomatic respiratory infections.</p>\",\"PeriodicalId\":10271,\"journal\":{\"name\":\"Clinical and Vaccine Immunology\",\"volume\":\"23 11\",\"pages\":\"878-883\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1128/CVI.00341-16\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Vaccine Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1128/CVI.00341-16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/11/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00341-16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/11/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 10

摘要

保守蛋白抗原已被研究作为抗呼吸道病原体的候选疫苗。我们评估了儿童时期抗肺炎链球菌、流感嗜血杆菌和卡他莫拉菌蛋白抗体的自然发展。从50名健康儿童的头一个月至13岁(中位采样间隔为6个月)收集血清样本。我们还分析了24名成年人的血清样本。血清IgG抗体针对八种肺炎球菌蛋白(Ply、CbpA、PspA 1和2、PcpA、PhtD、StkP-C和PcsB-N)、三种流感嗜血杆菌蛋白和五种卡塔卡分枝杆菌蛋白进行检测。采用多水平混合效应回归和Spearman相关分析抗体水平。抗肺炎球菌蛋白的抗体水平在3至5岁时达到峰值,然后达到平稳期。抗流感嗜血杆菌蛋白的抗体水平在第二年达到峰值,然后稳定下来。抗卡他氏分枝杆菌蛋白的抗体水平在第一年达到峰值,然后缓慢下降。儿童时期抗体峰值水平高于成人。肺炎球菌抗体水平在抗cbpa、抗pcpa和抗phtd抗体之间的相关性最高(r = 0.71 ~ 0.75;P < 0.001)。586例儿童出现854例有症状的呼吸道感染。在回归模型中,有症状的呼吸道感染并没有改善抗体水平的预测。针对所研究的肺炎球菌蛋白的免疫反应成熟具有相似性,特别是在CbpA, PcpA和PhtD之间。针对流感嗜血杆菌和卡他利分枝杆菌蛋白质的抗体产生在生命早期开始,并在针对肺炎球菌蛋白质的抗体产生之前达到峰值水平。基础抗体水平与症状性呼吸道感染的发生无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.

Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.

Conserved protein antigens have been investigated as vaccine candidates against respiratory pathogens. We evaluated the natural development of antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis proteins during childhood. Serum samples were collected from 50 healthy children from their first months to age 13 years (median sampling interval, 6 months). We also analyzed serum samples from 24 adults. Serum IgG antibodies against eight pneumococcal proteins (Ply, CbpA, PspA 1 and 2, PcpA, PhtD, StkP-C, and PcsB-N), three H. influenzae proteins, and five M. catarrhalis proteins were measured using a multiplexed bead-based immunoassay. Antibody levels were analyzed using multilevel mixed-effects regression and Spearman's correlation. Antibody levels against pneumococcal proteins peaked at 3 to 5 years of age and then reached a plateau. Antibody levels against H. influenzae proteins peaked during the second year and then stabilized. Antibody levels against M. catarrhalis proteins peaked during the first year and then slowly decreased. Peak antibody levels during childhood were higher than those of adults. Correlations among pneumococcal antibody levels were highest among anti-CbpA, anti-PcpA, and anti-PhtD antibodies (r = 0.71 to 0.75; P < 0.001). The children presented 854 symptomatic respiratory infections on 586 occasions. Symptomatic respiratory infections did not improve prediction of antibody levels in the regression model. The maturation of immune responses against the investigated pneumococcal proteins shares similarities, especially among CbpA, PcpA, and PhtD. Antibody production against H. influenzae and M. catarrhalis proteins starts early in life and reaches peak levels earlier than antibody production against the pneumococcal proteins. Basal antibody levels are not related to the occurrence of symptomatic respiratory infections.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical and Vaccine Immunology
Clinical and Vaccine Immunology 医学-传染病学
CiteScore
2.88
自引率
0.00%
发文量
0
审稿时长
1.5 months
期刊介绍: Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信